By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Cepheid were down around 1 percent in late Thursday trade after investment bank Thomas Weisel Partners downgraded the firm's stock to "market weight" from "overweight."

However, Thomas Weisel analyst Peter Lawson raised his price target on the stock from $18 to $20.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.